X4 Pharmaceuticals (XFOR) Reports In-Line Q2 EPS

X4 Pharmaceuticals (NASDAQ: XFOR) reported Q2 EPS of ($0.74), in-line with the analyst estimate of ($0.74).

For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.

You May Also Be Interested In

• Charles Schwab (SCHW) EPS edges past estimates, revenue up sequentially but dips YoY
• Orgenesis (ORGS) Issues Year End Business Update
• Goldman Sachs (GS) Tops Q1 EPS by $2.84